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Abstract
PTPRCAP (CD45-AP) is a positive regulator of protein tyrosine phosphatase PTPRC (CD45), which activates Src family
kinases implicated in tumorigenesis. Single-nucleotide polymorphism (SNP) rs869736 located at position −309 of
the PTPRCAP promoter was associated with susceptibility to diffuse-type gastric cancer in the current case-control
study. The minor-allele homozygote was significantly associated with a 2.5-fold increased susceptibility to diffuse-
type gastric cancer (P = .0021, n = 252), but not to intestinal-type (P = .30, n = 178), versus the major-allele homo-
zygote, when comparing unrelated Korean patients with healthy controls (n = 406). Nine other SNPs were in nearly
perfect linkage disequilibrium (r2 ≥ 0.97) with this SNP, exhibiting the same association, and spread out for 26 kb on
chromosome 11q13.1 covering RPS6KB2, PTPRCAP, CORO1B, and GPR152. Among the four genes, however, only
PTPRCAP expression was affected by haplotypes of the 10 SNPs. Endogenous transcript levels of PTPRCAP were
linearly correlated with copy numbers (0, 1, and 2) of the risk-haplotype (P= .0060) in 12 lymphoblastoid cells derived
from blood samples, but those of the other three genes were not. Furthermore, the cancer-risk, minor-allele T of
rs869736 increased both promoter activity and specific nuclear protein-binding affinity than the nonrisk, major-allele
G in luciferase reporter and electrophoretic mobility shift assays, respectively. Accordingly, the minor allele of
rs869736 in the PTPRCAP promoter is associated with increased susceptibility to diffuse-type gastric cancer by in-
creasing PTPRCAP expression, possibly leading to activation of the oncogenic Src family kinases.
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Introduction
Gastric cancer is a complex disease, and many environmental and
genetic factors are involved in its development. Helicobacter pylori in-
fection, smoking, and dietary habits are well-established environ-
mental risk factors [1–4]. Human genetic polymorphisms of IL1B,
IL1R2, IL10, TLR4, TNF, and PSCA have been associated with sus-
ceptibility to gastric cancer [5–8]. All of these, except for PSCA, are
related to proinflammatory signals and may accelerate the cancerous
changes such as inflammation, hypochlorhydria, and atrophic gastri-
tis, which can explain the sequential events of intestinal-type gastric
carcinogenesis. PSCA was identified as a diffuse-type gastric cancer
gene in a genome-wide association study and is possibly involved
in regulating gastric epithelial cell proliferation [8].
Notably, most genetic associations identified to date are specific
for histologic subtypes of gastric cancer, and it reflects their distinct
features in histologic, pathologic, and epidemiological aspects [9].
Intestinal-type gastric cancer develops through a series of precancerous
changes known as Correa sequence, superficial gastritis, chronic atro-
phic gastritis, intestinal metaplasia, dysplasia, and adenocarcinoma
[10]. In contrast, diffuse-type gastric cancer is not associated with atro-
phic gastritis or intestinal metaplasia, and lacks well-recognized precur-
sor changes [11–13]. H. pylori gastritis is the only common precursor
and a major risk factor in both types of gastric cancer [2,11].
Reversible tyrosine phosphorylation, which is regulated by the bal-
anced yin-yang (complementary opposites within a greater whole)
action of protein tyrosine kinases and protein tyrosine phosphatases,
plays an important role in cell proliferation, adhesion, and migration
[14]. The dynamic interactions between protein tyrosine kinases and
phosphatases act as molecular switches for signal transduction path-
ways [15], and deregulated protein tyrosine phosphorylation is asso-
ciated with tumorigenesis [14]. The protein tyrosine phosphatase
receptor type C (PTPRC), also known as CD45, transmits important
cellular signals by dephosphorylating the inhibitory tyrosine residue
of Src family kinases (SFKs) [16], which are implicated in tumor pro-
gression and metastasis [17,18]. The phosphatase activity of PTPRC
is enhanced by interaction with a transmembrane protein, PTPRC-
associated protein (PTPRCAP), also known as CD45-AP [19–22].
However, little is known about the relation between PTPRCAP
and gastric cancer.
In this study, the first evidence for genetic association of PTPRCAP
with susceptibility to diffuse-type gastric cancer is presented. A pro-
moter single-nucleotide polymorphism (SNP) G>T at position −309
of PTPRCAP affects the promoter activity and is associated with
in vivo expression levels of PTPRCAP and susceptibility to diffuse-type
gastric cancer.
Materials and Methods
Study Subjects
This study included 836 unrelated Korean subjects including 430 pa-
tients with gastric cancer and 406 healthy controls. The gastric can-
cers were classified either diffuse- (n = 252) or intestinal-type (n =
178) according to the Lauren system by two independent patholo-
gists, and the mixed-type or ambiguous cases were not included in
the study. The tumor stages at diagnosis were diverse: stage IA (n =
42), IB (n = 66), II (n = 86), IIIA (n = 106), IIIB (n = 58), and
IV (n = 72) according to the AJCC Cancer Staging Manual, and 58
of them were early and 372 were advanced gastric carcinoma by
tumor depth. All the controls were confirmed free of the disease
by health examinations including an endoscopy or an upper gastro-
intestinal track radiography. Patients were aged 57.3 ± 12.9 years
(mean ± SD), ranging from 23 to 86 years, whereas the controls
were 52.1 ± 8.4 years old, ranging from 39 to 76 years. The
male-to-female ratio was 2.0 in patients and 2.3 in controls. These
subjects were recruited with written informed consent at Seoul Na-
tional University Hospital, Hanyang University Guri Hospital, and
Inje University Seoul Paik Hospital in the Seoul metropolitan area
and at Chungnam National University Hospital and Eulji Uni-
versity Hospital in Daejeon city, with an approval from the insti-
tutional review board of Hanyang University Medical Center, and
genotyped with an approval from the institutional review board
of KAIST.
Genotyping and Sequencing
Genomic DNA was extracted from blood samples using the Pure-
gene DNA purification kit (Gentra, Minneapolis, MN) or from frozen
nontumorous gastric tissues using DNeasy tissue kit (Qiagen, Hilden,
Germany), and quantified using the double-stranded DNA-specific
fluorescent dye, PicoGreen (Molecular Probes, Eugene, OR). The final
concentration of each DNA sample was adjusted to 2.5 to 10 ng/μl
for genotyping assays. SNPs were genotyped using the MassARRAY
system (Sequenom, San Diego, CA) according to the manufacturer’s
instructions. The overall genotyping success rate was 99.6% for the
23 SNPs, and genotype frequencies of the control subjects in all SNPs
were under Hardy-Weinberg equilibrium.
Polymerase chain reaction (PCR) was performed using Pfu DNA
polymerase (Solgent, Daejeon, Korea), and the products were purified
from agarose gels using AccuPrep gel purification kit (Bioneer, Daejeon,
Korea). Genomic DNA from two subjects, a younger (43 years old)
patient with an advanced (stage IV) diffuse-type gastric cancer and
an older (69 years old) healthy control were sequenced by the Solgent
Corp. All primers for genotyping and sequencing analysis were synthe-
sized by the Bioneer Corp.
Statistical Analyses
Allelic association of individual SNP with susceptibility to diffuse-
or intestinal-type gastric cancer and Hardy-Weinberg equilibrium in
the control subjects were assessed by χ 2 tests. Haplotypes were con-
structed using PHASE 2.1 and linkage disequilibrium (LD) maps
using Haploview 4.1 [23–25]. In logistic regression analyses of geno-
type and diplotype associations, odds ratio (OR) and 95% confi-
dence interval (CI) were adjusted for age and sex using SPSS 11.5
because the age distribution and sex ratio were different between
the cases and controls.
Real-time Reverse Transcription–PCR
Genomic DNA was isolated from 12 lymphoblastoid cell lines and
genotyped for rs1808279. Total RNA was extracted using NucleoSpin
(Macherey-Nagel, Düren, Germany), and the first-strand complemen-
tary DNA was synthesized using an oligo(dT) primer and Improm-II
reverse transcription (Promega, Madison, WI). Real-time PCR was
performed using the Bio-Rad iQ SYBR Green Supermix and iCycler
iQ5 machine. The first-strand complementary DNA and RNA (as a
negative control) samples were amplified for four genes (PTPRCAP,
RPS6KB2, CORO1B, and GPR152), and the amounts were normal-
ized against that of GAPDH.
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Luciferase Reporter Assays
DNA segments containing one of the two alleles in an SNP was am-
plified by PCR using Pfu DNA polymerase (Solgent) and cloned into
the KpnI and XhoI sites of pGL3-Basic vector (Promega) or to the XbaI
site of pGL3-Promoter vector. Especially, a PTPRCAP promoter region
was amplified using previously reported primer sequences [26]. All the
recombinant constructions were confirmed by sequencing analysis.
MKN28 cells (2 × 105),maintained inRPMI1640 (Gibco, Rockville,
MD) supplemented with 10% fetal bovine serum (Hyclone, Logan,
UT), were transfected with 1 μg of plasmid and 50 ng of pRL-CMV
control vector in 12-well tissue culture plates using Lipofectamine
LTX reagent (Invitrogen, Carlsbad, CA). Cells were harvested at
36 hours after transfection, and luciferase activities were measured using
the dual-luciferase reporter assay system (Promega). All experiments
were performed in triplicate.
Electrophoretic Mobility Shift Assays
Double-stranded oligonucleotides for electrophoretic mobility shift
assay (EMSA) were generated using complementary oligonucleotides
5′-AACCTGGAGACAGAGGATGTCACAGGAGT-3′ and 5′-
ACTCCTGTGACATCCTCTGTCTCCAGGTT-3′ for the −309G
carrier, and 5′-AACCTGGAGACAGATGATGTCACAGGAGT-3′
and 5′-ACTCCTGTGACATCATCTGTCTCCAGGTT-3′ for the
−309T carrier (the SNP-corresponding position is underlined). Double-
stranded probes were radioactively labeled with [γ-32P]dATP (Perkin
Elmer, Wellesley, MA) at the 5′ ends using the T4 polynucleotide ki-
nase (Takara Bio, Shiga, Japan), and unincorporated [γ -32P]dATPwas
removed using the PROBER probe DNA purifying system (iNtRON
Biotechnology, Seongnam, Korea).
A nuclear extract (8 μg) from MKN28 cells and 0.6 μg of poly(dI-
dC) were preincubated with or without 200-fold molar excess of
unlabeled competitor in 1× EMSA reaction buffer (10 mM HEPES-
KOH, pH 7.9, 60 mM KCl, 1 mM EDTA, 10% glycerol, 10 mM
MgCl2, and 200 μM dithiothreitol) for 20 minutes at room tem-
perature. Incubation was continued with addition of a radioactively
labeled probe (80 fmol) for another 20 minutes at room temperature.
The whole 20 μl of the reaction product was subjected to gel electro-
phoresis (6% polyacrylamide gel in 0.25× Tris/borate/EDTA running
buffer at 180 V for 2.5 hours). Finally, the gel was scanned by BAS-
3000 (Fujifilm, Tokyo, Japan).
Prediction for Transcription Factor Binding
Transcription factors that can bind to the PTPRCAP SNP rs869736
at position −309 in an allele-specific manner were predicted for the two
30-bp sequences, 5′-AACCTGGAGACAGA[G/T]GATGTCACAG-
GAGTC-3′ using seven different programs: AliBaba 2.1 (BIOBASE,
Wolfenbuettel,Germany),Match 1.0 (BIOBASE),MatInspector (Genomatix,
Munich, Germany), Patch 1.0 (BIOBASE), TESS (http://www.cbil.
upenn.edu/cgi-bin/tess/tess), TFSEARCH (http://www.cbrc.jp/research/
db/TFSEARCH.html), and Tfsitescan (http://www.ifti.org/cgi-bin/ifti/
Tfsitescan.pl). Their default settings were used, but target organisms were
restricted to vertebrates or mammalians.
Results
A 26-kb Locus on 11q13.1 Associated with Diffuse-type
Gastric Cancer
Many SNPs around the PTPRCAP gene on human chromosome
11q13.1 were in high LD with one another according to the geno-
type data from the International HapMap Project (Figure 1A). From
a 430-kb region surrounding PTPRCAP, 18 SNPs were selected and
genotyped for 252 unrelated Korean patients with diffuse-type gastric
cancer and 406 healthy controls. Among them, seven SNPs (rs1476792
and rs1790753 in RPS6KB2; rs869736 in PTPTCAP, rs872375,
rs2302264, and rs1808279 in CORO1B; and rs1790761 in GPR152)
showed significant allelic associations with susceptibility to diffuse-
type gastric cancer (Table 1).
These seven associated SNPs were very tightly linked to each other
(r2 ≥ 0.97), together constituting an LD block of 26 kb, and other
11 SNPs located outside this LD block were not associated (Figure 1A).
Thus, a gastric cancer susceptibility locus was localized to a 26-kb block
containing four genes, RPS6KB2, PTPRCAP, CORO1B, and GPR152
by the seven SNPs very tightly linked together (Figure 1B).
Haplotypes Associated with Diffuse-type Gastric Cancer
To find more polymorphisms that are tightly linked to the seven
associated SNPs and potentially affect protein activity or gene expres-
sion, all the exons, exon-intron junctions, and promoters (1-1.5 kb from
the transcription start site) of the four genes in genomic DNA from
two extreme individuals were sequenced. The two individuals were a
younger patient with an advanced diffuse-type gastric cancer who was
homozygous for the seven risk alleles and an older healthy control ho-
mozygous for the nonrisk alleles. Between the two individuals, the alleles
were also different in five additional SNPs, all located in RPS6KB2:
rs55987642, rs13859, rs4930427, rs10274, and rs1790752. Geno-
typing of these additional five SNPs disclosed that only three of them,
rs4930427, rs1790752, and rs13859, were significantly associated with
the diffuse-type gastric cancer (Table 1). From a total of 23 SNPs tested,
10 SNPs were significantly associated with diffuse-type gastric cancer
and in nearly perfect LD with each other (r2 ≥ 0.97).
All the 10 SNPs passed a significance level of association adjusted
for multiple testing. The adjusted significance level (α = 1 − (1 −
0.05)1/13.86 = 0.0037) was calculated with the effective degree of free-
dom estimated for the set of SNP genotypes in LD, using the EDF
software [27].Moreover, four SNPs of these passed even the significance
level of Bonferroni correction (α = 1 − (1 − 0.05)1/23 = 0.0022) for
multiple testing; however, the Bonferroni method could be an over-
correction in cases with very tightly linked SNPs, similar to this case.
When haplotypes were constructed with the 10 significantly asso-
ciated SNPs (their P values are underlined in Table 1), two haplo-
types, TCGCCGGGAA (designated as H1) and CTATTTAAGG
(H2), in the order of SNP nucleotide positions listed in Table 1, con-
stituted 98.1% of entire haplotypes, and only a small portion of the
subjects had other haplotypes (1.4% in controls and 2.8% in diffuse-
type cancer patients). The H2 haplotype with the risk allele at every
SNP was significantly associated with susceptibility to diffuse-type can-
cer (OR = 1.43, P = .00340) versus the H1 with the nonrisk alleles
at all SNPs. Logistic regression analysis of diplotype association re-
vealed 2.50- and 1.46-fold higher odds of having diffuse-type cancer
in the H2/H2 homozygotes (P = .0021) and H1/H2 heterozygotes
(P = .030), respectively, in comparison with the H1/H1 homozygotes
(Table 2). Thus, the 10-SNP haplotypes were associated with suscep-
tibility to diffuse-type gastric cancer.
Association of the Risk Haplotype with Increased In Vivo
Transcript Levels of PTPRCAP
As explained in the previous section, a diffuse-type gastric cancer
susceptibility locus was mapped to a 26-kb region, which contains four
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genes, RPS6KB2, PTPRCAP, CORO1B, and GPR152 (Figure 1B).
Because the strong LD of this locus did not allow for a further fine
mapping by association analysis, functional analyses were then tried
to identify the susceptibility gene(s). Abnormal protein activity or al-
tered gene expression may cause an increased susceptibility to cancer.
In this susceptibility locus, two coding SNPs in RPS6KB2 showed sig-
nificant association, but there was no amino acid change (Phe269)
in rs4930427 or the change was too small (Ala420Val) in rs13859
to alter protein activity dramatically.
The next step involved investigating whether expression of any
of the four genes was altered by the risk haplotype in vivo. Twelve
Figure 1. Association profile and LD map of all 23 tested SNPs. (A) P values in negative logarithm (y axis) for allelic associations with
diffuse-type gastric cancer susceptibility are shown against chromosome positions (x axis) of 23 SNPs in the upper half. An LD map of
430-kb region generated by the genotype data of 56 SNPs with minor allele frequencies of 0.1 or higher in the International HapMap CHB +
JPT population is shown in the lower half. (B) A detailed view of the 30-kb region boxed in A. The region contains four genes and the
10 SNPs significantly associated with the susceptibility to diffuse-type gastric cancer (.0013 ≤ P ≤ .0036).
Table 1. Allelic Association Tests of 23 SNPs with Diffuse-type Gastric Cancer.
SNP Gene Function Allele* MAF† OR (95% CI)‡ P ‡
rs2282502 RHOD Asp88 C>T 0.42 0.95 (0.75-1.18) .62
rs10791899 Intergenic A>C 0.22 1.28 (0.99-1.66) .060
rs3927807 FBXL11 Intron G>A 0.23 1.29 (1-1.67) .050
rs1790740 Intergenic T>C 0.23 1.28 (0.99-1.65) .056
rs7480390 Intergenic C>G 0.23 1.33 (1.03-1.71) .030
rs10896172 TBC1D10C Intron T>C 0.18 1.13 (0.85-1.5) .39
rs1790733 KIAA1394 Intron T>C 0.25 1.34 (1.05-1.72) .020
rs1476792 RPS6KB2 Intron T>C 0.29 1.44 (1.13-1.82) .0026
rs917570 RPS6KB2 Intron C>G 0.18 1.16 (0.87-1.54) .32
rs55987642 RPS6KB2 Pro267Leu C>T 0.07 1.08 (0.7-1.67) .74
rs4930427 RPS6KB2 Phe269 C>T 0.29 1.43 (1.12-1.81) .0033
rs1790753 RPS6KB2 Intron G>A 0.29 1.46 (1.15-1.85) .0017
rs1790752 RPS6KB2 Intron C>T 0.29 1.46 (1.15-1.85) .0017
rs13859 RPS6KB2 Ala420Val C>T 0.29 1.44 (1.13-1.82) .0026
rs10274 RPS6KB2 3′ UTR G>A 0.25 1.36 (1.06-1.75) .014
rs869736 PTPRCAP Promoter G>T 0.29 1.45 (1.14-1.83) .0020
rs872375 CORO1B Intron G>A 0.29 1.42 (1.12-1.8) .0036
rs2302264 CORO1B Intron G>A 0.29 1.43 (1.13-1.81) .0028
rs1808279 CORO1B Promoter A>G 0.29 1.47 (1.16-1.86) .0013
rs1790761 GPR152 Promoter A>G 0.29 1.44 (1.14-1.82) .0024
rs17501521 CABP4 Intron C>T 0.11 1.22 (0.87-1.72) .25
rs4084113 AIP Intron G>A 0.18 1.24 (0.94-1.64) .12
rs2276120 PITPNM1 Intron C>T 0.18 1.23 (0.93-1.62) .15
Significant values after correction for multiple testing (P ≤ .0037) are underlined.
*Major allele > minor allele.
†Minor allele frequency in controls.
‡Crude OR, 95% CI, and P for allelic association test.
Table 2. Association of Haplotypes with Diffuse-type Gastric Cancer.
Category Control Diffuse-type OR (95% CI)* P *
Haplotype† 2n = 812 2n = 504
H1 (TCGCCGGGAA) 571 (70.3%) 311 (61.7%) 1
H2 (CTATTTAAGG) 230 (28.3%) 179 (35.5%) 1.43 (1.12-1.82) .0034
Others 11 (1.4%) 14 (2.8%)
Diplotype n = 406 n = 252
H1/H1 196 (48.3%) 92 (36.5%) 1
H1/H2 176 (43.3%) 118 (46.8%) 1.46 (1.04-2.07) .030
H2/H2 27 (6.7%) 30 (11.9%) 2.50 (1.39-4.47) .0021
Others 7 (1.7%) 12 (4.8%)
*Crude OR, 95% CI, and P values calculated in χ 2 tests for haplotype association, and age/sex–
adjusted OR, 95% CI, and P values calculated in logistic regression analysis for diplotype association.
†In each haplotype, the alleles are listed in the SNP order of rs1476792, rs4930427, rs1790753,
rs1790752, rs13859, rs869736, rs872375, rs2302264, rs1808279, and rs1790761.
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lymphoblastoid cell lines derived from healthy individuals were geno-
typed for rs1808279, which was almost perfectly linked to all the
other haplotype-constituent SNPs (r2 ≥ 0.97) and was most signifi-
cantly associated with the diffuse-type cancer (P = .0013). They were
categorized into three groups according to their diplotypes that were
estimated by their rs1808279 genotypes: five samples were homo-
zygous for the nonrisk haplotype (H1/H1), five samples were hetero-
zygous (H1/H2), and two samples were homozygous for the risk
haplotype (H2/H2). Total RNA was isolated from each cell line and
expression levels of the four endogenous genes were measured by real-
time reverse transcription–PCR, except for those of GPR152, which
were too low to make reliable measurements.
As shown in Figure 2, the risk-haplotype copy number was signif-
icantly correlated with the endogenous transcript levels of PTPRCAP
(P = .0060) in linear regression analysis but not with those of
RPS6KB2 (P = .29) or CORO1B (P = .53). The linear correlation
was positive, supporting for association of PTPRCAP expression with
the risk haplotype in an additive genetic model (Figure 2). PTPRCAP
transcript levels of the H2/H2 homozygotes and H1/H2 heterozygotes
were 35% and 18% higher than those of the H1/H1 homozygotes,
respectively. Thus, the diffuse-type gastric cancer risk haplotype was
associated with increased endogenous transcript levels of PTPRCAP
but not with those of RPS6KB2, CORO1B, or GPR152.
A Promoter SNP at Position −309 in PTPRCAP Affecting
Promoter Activity
The alteration of PTPRCAP transcript levels depending on the risk-
haplotype copy number could be attributed to one SNP, rs869736
G>T, which was cancer-associated and located at position −309 of
the PTPRCAP promoter. Contribution of this SNP to the altered gene
expression was evaluated using luciferase reporter assays. A 610-bp
DNA segment (from position −580 to +30) with either risk or non-
risk allele at the SNP was cloned upstream of the luciferase gene in
the pGL3-Basic plasmid, and luciferase activities were measured in
MKN28 gastric cancer cells (Figure 3). The luciferase levels relative
to the empty vector were 55% higher in the construct of the risk allele
T-carrying promoter than in the nonrisk G carrier (P = .00039 in one-
way analysis of variance). Thus, the risk allele T at position −309 of
PTPRCAP increased the promoter activity and gene expression.
Three other cancer-associated SNPs, namely, rs10274, rs1808279,
and rs1790761, were located in the 3′ untranslated region (UTR) of
RPS6KB2 and in the promoter regions of CORO1B and GPR152,
respectively, and were also tested for possibility of altering gene expres-
sion. The DNA segments containing a promoter SNP were cloned
into the pGL3-Basic upstream of the luciferase gene, and those con-
taining a 3′-UTR SNP were cloned into the pGL3-Promoter plasmid
downstream of the luciferase gene. No allelic difference was detected in
luciferase activity with respect to the UTR SNP in RPS6KB2 or the
promoter SNP in CORO1B (Figure 3), and no luciferase activity was
observed with the constructs of the promoter SNP in GPR152. Thus,
alternations of gene expression by the three SNPs were not observed.
Specific Nuclear Protein Binding to the −309 SNP
in PTPRCAP
Because the SNP at position −309 of PTPRCAP affected the pro-
moter activity, a possibility of its binding to a nuclear transcription
Figure 2. Relationship between the haplotypes and gene expression levels. Relative endogenous transcript levels of RPS6KB2 (A), PTPRCAP
(B), and CORO1B (C) were measured in five lymphoblastoid cell lines homozygous for the nonrisk haplotype (H1/H1), five heterozygotes
(H1/H2), and two homozygotes with the risk haplotype (H2/H2) using real-time reverse transcription–PCR and displayed in box plots. The
linear regression coefficient (R2) and P values are shown. The haplotypes were estimated by the genotypes of rs1808279.
Figure 3. Luciferase reporter assays for evaluating allelic difference
in regulatory activity of the associated SNPs. A promoter fragment
with the risk or nonrisk allele in rs869736 (PTPRCAP) or rs1808279
(CORO1B) was clonedupstreamof the luciferase gene inpGL3-Basic
vector, and a 3′-UTR fragment with either allele in rs10274 (RPS6KB2)
downstream of the gene in pGL3-Promoter vector. Relative lucif-
erase activities were measured in the MKN28 gastric cancer cell
line in triplicate. P values were calculated by one-way analysis of var-
iance tests.
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factor was tested using EMSA. Nuclear extracts from MKN28 cells
and two radioactively labeled oligonucleotides of 29 bp carrying G or
T in the SNP-corresponding position were used for the assays (Fig-
ure 4). A shifted band was observed with both variants, but the band
intensity was much higher with the T-carrying variant (lane 6 ) than
the G variant (lane 2). With 200-fold excess amounts of unlabeled
probes of the two variants used in separate assays, the band intensities
were markedly reduced for both variants (lanes 3, 4, 7, and 8), but the
T variant showed a stronger competition than G variant (lanes 7 vs 8);
this was consistent with the observation made earlier that the T variant
had a stronger promoter activity than the G variant. Thus, the risk allele
T at position −309 of PTPRCAP increased the specific affinity to a nu-
clear protein present in MKN28 cells versus the nonrisk allele G.
No Association with Intestinal-type Gastric Cancer
To test association of rs869736 at position −309 of PTPRCAP with
susceptibility to intestinal-type gastric cancer, 178 unrelated patients
with intestinal-type gastric cancer were additionally genotyped and
compared with the 406 healthy controls. Either alleles or genotypes
were not significantly associated with susceptibility to intestinal-type
gastric cancer (Table 3). Although the minor allele T was more fre-
quent in both diffuse- (37.1%) and intestinal-type (33.7%) cancers
than in the controls (28.9%), the difference was significant only in
diffuse-type cancer (diffuse-type, OR = 1.45, P = .0020, intestinal-type,
OR = 1.25, P = .10). In logistic regression analysis, TT and GT geno-
types showed 2.47- and 1.45-fold higher odds of having diffuse-type
cancer than the GG genotype, respectively (P = .0021 and P = .031,
respectively); however, the genotypes were not significantly associated
with intestinal-type cancer risk (P = .30 and P = .87, respectively;
Table 3). Thus, the association of rs869736 was specific for diffuse-type
gastric cancer.
Discussion
This study is the first to find that PTPRCAP is a gastric cancer suscep-
tibility gene specific to diffuse-type. The minor allele in SNP rs869736
(G>T) located at position −309 of the PTPRCAP promoter was sig-
nificantly associated with a 1.45-fold increased susceptibility to diffuse-
type gastric cancer versus the major allele (P = .0020). The minor-allele
homozygote had a 2.47-fold higher odds than the major-allele homo-
zygote (P = .0021). In contrast, either the alleles or genotypes were
not significantly associated with susceptibility to intestinal-type gas-
tric cancer. The results are consistent with a previous study that stated
that the two types of gastric cancer develop through distinct pathways
[11], although this type-specific association needs to be confirmed in
other populations.
When compared with the nonrisk major allele G, the cancer-risk
minor allele T at this SNP was observed to increase both promoter
activity and the affinity to a nuclear protein, and as a consequence,
the gene expression in vitro and in vivo. These results confirm that
PTPRCAP expression is higher in human diffuse-type gastric cancer tis-
sues compared with corresponding normal tissues [28]. The 1.55-fold
difference in promoter activity between the two alleles observed in
the luciferase assays conducted for this study using MKN28 gastric
cancer cell lines is qualitatively consistent with the 2- and 1.3-fold
differences in previous assays performed by other researchers using
HEK297Tand TE671 cell lines, respectively [26]. Several transcription
activators such as AP-1, c-Jun, c-Fos, and CREB are predicted to prefer
the T allele to G allele at this SNP based on the known sequence spec-
ificities of these transcription factors. Thus, the risk allele at position
−309 of the PTPRCAP promoter could increase cancer susceptibility
by enhancing PTPRCAP expression.
PTPRCAP (or CD45-AP) are functionally linked to the proto-
oncogenic SFKs, which, in an activated state, transmit various cellular
signals toward aberrant proliferation, increased motility and invasive-
ness, resistance to apoptosis, and increased angiogenesis [17]. SFK
can be inhibited by phosphorylation of a carboxyl-terminal tyrosine
residue, but this inhibitory phosphate group can be removed by the
protein tyrosine phosphatase PTPRC (or CD45), leading to activation
Figure 4. Electrophoreticmobility shift assaysusingDNAprobeswith
the−309 SNP in PTPRCAP. A nuclear extract (8 μg) fromMKN28 cells
was incubated with a 29-bp [γ-32P]dATP-labeled DNA probe with ei-
ther major (G) or minor (T) allele at the SNP-corresponding position
(lanes 2 and 6). For competition assays, unlabeled DNA (200-fold
excess) were pre-incubated with the nuclear extract before addition
of the labeled probes (lanes 3, 4, 7, and 8).
Table 3. Type Specificity in Genotypic Association of rs869736 with Gastric Cancer Susceptibility.
Genotype Control (n = 406) Diffuse-type Gastric Cancer Patient Intestinal-type Gastric Cancer Patient
(n = 252) OR (95% CI)* P (n = 178) OR (95% CI)* P
GG 198 (48.8%) 96 (38.1%) 1 76 (42.7%) 1
GT 181 (44.6%) 125 (49.6%) 1.45 (1.04-2.03) .031 84 (47.2%) 1.03 (0.68-1.56) .87
TT 27 (6.7%) 31 (12.3%) 2.47 (1.39-4.40) .0021 18 (10.1%) 1.52 (0.72-3.20) .30
*Age- and sex-adjusted OR and 95% CI in multivariate logistic regression.
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of SFK [29–31]. The phosphatase activity of PTPRC is enhanced
[32], and its interaction with SFK is stabilized when PTPRC dimer
formation is inhibited by binding to PTPRCAP [22,33]. Thus,
PTPRCAP binding to PTPRC can result in activation of SFK.
Overproduction or hyperactivation of SFK has been observed in a va-
riety of human epithelial cancers [17] and is known to disrupt cell-cell
adhesion [34,35], by inducing impairment in themembrane localization
of E-cadherin (CDH1) [36], and to promote gain of invasive proper-
ties of epithelial cells [37]. Notably, down-regulation of CDH1 is a rec-
ognized feature of diffuse-type gastric cancer [38], and mutations in
CDH1 have been found in hereditary diffuse-type gastric cancer [39].
Accordingly, a possible hypothesis is that enhanced levels of PTPRCAP
facilitate activation of SFK and, consequently, impair E-cadherin func-
tion to increase susceptibility to diffuse-type gastric tumorigenesis.
In H. pylori infection, SFK can phosphorylate CagA of H. pylori to
activate a cellular oncoprotein PTPN11 (or SHP2) [40], which is
known to induce the sequential changes of intestinal-type gastric car-
cinogenesis [41]. Alternatively, PTPRCAP has been shown to en-
hance the sensitivity of T-cell receptor signaling through activation
of SFK in hematopoietic cells [20,21,32,42], which may exacerbate
inflammation and offer an attractive microenvironment for tumor
growth, facilitate genomic instability, and promote angiogenesis
[43,44]. However, these possibilities are yet unknown for diffuse-
type gastric tumorigenesis.
Ten SNPs of the cancer-associated haplotype discovered in this
study are dispersed in four genes, RPS6KB2, PTPRCAP, CORO1B,
and GPR152 (Figure 1B). Among them, PTPRCAP was identified to
be functionally associated with the gastric cancer because 1) the en-
dogenous transcript levels of PTPRCAP alone were linearly correlated
with the risk haplotype copy number and 2) the promoter activity
was increased by the risk allele at a promoter SNP of PTPRCAP com-
pared with the nonrisk allele. Associations of the other nine SNPs,
especially those showing no functional variation in this study, were
probably because of their very high linkage disequilibria with the
PTPRCAP promoter SNP. However, a possibility of their functional
relevance in the cancer susceptibility should not be ruled out because
not all of these SNPs were examined for every possible function.
In conclusion, a promoter SNP rs869736 at position −309 of
PTPRCAP is associated with susceptibility to diffuse-type gastric
cancer rather than to intestinal-type gastric cancer. Its minor allele
T increases both promoter activity and promoter affinity to a nuclear
protein (presumably a transcription factor) and, as a consequence,
the gene expression. The resulting increase in cellular levels of
PTPRCAP can increase the susceptibility to gastric cancer, as it
might result in activation of the oncogenic SFKs and disruption of
cell-cell contacts mediated by E-cadherin, among other possibilities.
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